// startup autopsy
ARYx Therapeutics
Better-by-design drugs that couldn't prove better enough
marketfitSlow Death
Years-long decline before final shutdown · Fatal mistake: ARYx's 'retrometabolic' drug design platform failed to produce clinical results that clearly differentiated its candidates from cheaper existing treatments.
Key Events Timeline
FOUNDING
ARYx Therapeutics founded in the USA to develop retrometabolic drug design platform targeting safer versions of existing medicines.
FUNDING
ARYx raises significant venture capital to advance multiple cardiovascular and CNS drug candidates into clinical trials.
PRODUCT LAUNCH
Lead cardiovascular candidate enters Phase II trials. Early data shows modest but not compelling differentiation from existing drugs.
FUNDING
Final funding round closes at $83.3M total raised. Clinical setbacks force pipeline prioritization and headcount reduction.
SHUTDOWN
ARYx winds down operations after clinical programs fail to produce approvable data, having spent $83.3M over a decade.
MEDIA_MENTION
ARYx Therapeutics Inc said it would wind down its operations due to lack of funding after the U.S. health regulator delayed providing